Noxopharm (ASX:NOX) secured Human Research Ethics Committee approval for the Heracles clinical trial, a first-in-human trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, according to a Thursday filing with the Australian bourse.
The trial will assess SOF-SKN's safety profile at four concentrations, working with Doherty Clinical Trials in Melbourne to advance operational aspects like site initiation, batch preparation, and participant screening and recruitment, the filing said.
Shares rose 6% in afternoon trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.